{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:55:49Z","timestamp":1794048949052,"version":"4.8.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007232","name":"Radiumhemmets Forskningsfonder","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009782","name":"Ruth och Richard Julins Stiftelse","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009782","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009332","name":"Mag-TarmFonden, Swedish Gastroenterology Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009336","name":"Bengt Ihres Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Primary sclerosing cholangitis (PSC) is associated with an increased risk of hepatobiliary and colorectal cancer, but the risks of other cancer forms have not been explored. The aim of this study was to evaluate the risk of intestinal and extraintestinal cancers in a large, well-defined cohort of PSC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and method<\/jats:title>\n                    <jats:p>A matched cohort study of Swedish PSC patients was performed with up to ten comparators for each patient, matched for sex, age, and residency. The data were retrieved from national registers. Patients were followed from PSC diagnosis until cancer diagnosis, liver transplantation, first emigration date, death, or December 31, 2016. The risk of cancer was estimated using the Kaplan\u2013Meier method and Cox regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 1432 PSC patients with a verified diagnosis and 14,437 comparators were studied. The mean follow-up time was 15.9\u00a0years. Eighty-eight percent of the PSC patients had concomitant inflammatory bowel disease. PSC patients ran significantly increased risks of developing any cancer [HR 3.8, 95% confidence interval (CI) 3.3\u20134.3], hepatobiliary cancer (HR 120.9, 95% CI 72.0\u2013203.1), colorectal cancer (HR 7.5, 95% CI 5.6\u201310.0), pancreatic cancer (HR 8.0, 95% CI 3.2\u201320.2), gastric cancer (HR 4.2, 95% CI 1.5\u201311.3), small bowel cancer (HR 21.1, 95% CI 3.5\u2013128.2), and lymphoma (HR 3.0, 95% CI 1.6\u20135.7). PSC was not associated with a lower risk of any cancer form.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PSC patients have a four times overall increased risk of developing cancer compared to the general population, with increased risk of developing hepatobiliary, colorectal, and pancreatic cancer, as well as lymphoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12072-021-10214-6","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T06:08:26Z","timestamp":1628230106000},"page":"1174-1182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Increased risk of cancer in patients with primary sclerosing cholangitis"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5386-4385","authenticated-orcid":false,"given":"Aiva","family":"Lundberg B\u00e5ve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Bergquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bottai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Warnqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"von Seth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Nordenvall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,6]]},"reference":[{"issue":"1","key":"10214_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1055\/s-0038-1676099","volume":"39","author":"V Ranieri","year":"2019","unstructured":"Ranieri V, McKay K, Walmsley M, Senior R, Thorburn D, Kennedy E. Primary sclerosing cholangitis and psychological wellbeing: a scoping review. Semin Liver Dis 2019;39(1):104\u2013110","journal-title":"Semin Liver Dis"},{"issue":"58","key":"10214_CR2","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/hep.26565","volume":"2013","author":"KWR Boonstra","year":"2013","unstructured":"Boonstra KWR, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, van Nieuwkerk KM, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology2013;2013(58):2045\u20132055","journal-title":"Hepatology"},{"issue":"3","key":"10214_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0168-8278(01)00288-4","volume":"36","author":"A Bergquist","year":"2002","unstructured":"Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36(3):321","journal-title":"J Hepatol"},{"issue":"8","key":"10214_CR4","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","volume":"152","author":"TJ Weism\u00fcller","year":"2017","unstructured":"Weism\u00fcller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 2017;152(8):1975-1984.e8","journal-title":"Gastroenterology"},{"issue":"1","key":"10214_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1067\/mge.2002.125367","volume":"56","author":"RM Soetikno","year":"2002","unstructured":"Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002;56(1):48\u201354","journal-title":"Gastrointest Endosc"},{"issue":"9","key":"10214_CR6","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.crohns.2014.01.019","volume":"8","author":"AN Ananthakrishnan","year":"2014","unstructured":"Ananthakrishnan AN, Cagan A, Gainer VS, Cheng SC, Cai T, Szolovits P, et al. Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease. J Crohns Colitis 2014;8(9):956\u2013963","journal-title":"J Crohns Colitis"},{"key":"10214_CR7","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1053\/j.gastro.2020.05.049","volume":"159","author":"PJCH Trivedi","year":"2020","unstructured":"Trivedi PJCH, Mytton J, Bosch S, Iqbal T, Ferguson J, Hirschfield GM. Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel diseases, based on sex, race, and age. Gastroenterology 2020;159:915\u2013928","journal-title":"Gastroenterology"},{"issue":"1","key":"10214_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/00365521.2019.1707277","volume":"55","author":"N Barner-Rasmussen","year":"2020","unstructured":"Barner-Rasmussen N, Pukkala E, Jussila A, Farkkila M. Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. Scand J Gastroenterol 2020;55(1):74\u201381","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10214_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/apt.15785","volume":"52","author":"\u00c5H Everhov","year":"2020","unstructured":"Everhov \u00c5H, Erichsen R, Sachs MC, Pedersen L, Halfvarson J, Askling J, et al. Inflammatory bowel disease and pancreatic cancer: a Scandinavian register-based cohort study 1969\u20132017. Aliment Pharmacol Ther 2020;52(1):143\u2013154","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10214_CR10","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.autrev.2017.07.022","volume":"16","author":"E Giat","year":"2017","unstructured":"Giat E, Ehrenfeld M, Shoenfeld Y. Cancer and autoimmune diseases. Autoimmun Rev 2017;16(10):1049\u20131057","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10214_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/gut.2004.051771","volume":"54","author":"J Askling","year":"2005","unstructured":"Askling J, Brandt L, Lapidus A, Karl\u00e9n P, Bj\u00f6rkholm M, L\u00f6fberg R, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005;54(5):617\u2013622","journal-title":"Gut"},{"issue":"4","key":"10214_CR12","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1006\/bcmd.2001.0442","volume":"27","author":"M Ehrenfeld","year":"2001","unstructured":"Ehrenfeld M, Abu-Shakra M, Buskila D, Shoenfeld Y. The dual association between lymphoma and autoimmunity. Blood Cells Mol Dis 2001;27(4):750\u2013756","journal-title":"Blood Cells Mol Dis"},{"issue":"9","key":"10214_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","volume":"32","author":"HL Brooke","year":"2017","unstructured":"Brooke HL, Talb\u00e4ck M, H\u00f6rnblad J, Johansson LA, Ludvigsson JF, Druid H, et al. The Swedish cause of death register. Eur J Epidemiol 2017;32(9):765\u2013773","journal-title":"Eur J Epidemiol"},{"issue":"2","key":"10214_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10654-016-0117-y","volume":"31","author":"JF Ludvigsson","year":"2016","unstructured":"Ludvigsson JF, Almqvist C, Bonamy AK, Ljung R, Micha\u00eblsson K, Neovius M, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol 2016;31(2):125\u2013136","journal-title":"Eur J Epidemiol"},{"key":"10214_CR15","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011;11:450","journal-title":"BMC Public Health"},{"key":"10214_CR16","unstructured":"Sweden Nbohawi. Statistical databases. https:\/\/www.socialstyrelsen.se\/en\/statistics-and-data\/registers\/. Accessed 17 Oct 2019"},{"issue":"1","key":"10214_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/ije\/14.1.64","volume":"14","author":"B Mattsson","year":"1985","unstructured":"Mattsson B, Rutqvist LE, Wallgren A. Undernotification of diagnosed cancer cases to the Stockholm Cancer Registry. Int J Epidemiol 1985;14(1):64\u201369","journal-title":"Int J Epidemiol"},{"issue":"9","key":"10214_CR18","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1080\/00365521.2019.1660799","volume":"54","author":"JF Ludvigsson","year":"2019","unstructured":"Ludvigsson JF, Andersson M, Bengtsson J, Eberhardson M, Fagerberg UL, Grip O, et al. Swedish Inflammatory Bowel Disease Register (SWIBREG)\u2014a nationwide quality register. Scand J Gastroenterol 2019;54(9):1089\u20131101","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"10214_CR19","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","volume":"67","author":"TH Karlsen","year":"2017","unstructured":"Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis\u2014a comprehensive review. J Hepatol 2017;67(6):1298\u20131323","journal-title":"J Hepatol"},{"issue":"3","key":"10214_CR20","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/liv.13548","volume":"38","author":"J S\u00f8rensen","year":"2018","unstructured":"S\u00f8rensen J, Nielsen OH, Andersson M, Ainsworth MA, Ytting H, B\u00e9lard E, et al. Inflammatory bowel disease with primary sclerosing cholangitis: a Danish population-based cohort study 1977\u20132011. Liver Int 2018;38(3):532\u2013541","journal-title":"Liver Int"},{"issue":"3","key":"10214_CR21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.mcna.2016.01.006","volume":"100","author":"I Doycheva","year":"2016","unstructured":"Doycheva I, Amer S, Watt KD. De novo malignancies after transplantation: risk and surveillance strategies. Med Clin N Am 2016;100(3):551\u2013567","journal-title":"Med Clin N Am"},{"issue":"8","key":"10214_CR22","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1097\/TP.0000000000001725","volume":"101","author":"MA Mouchli","year":"2017","unstructured":"Mouchli MA, Singh S, Loftus EV Jr, Boardman L, Talwalkar J, Rosen CB, et al. Risk factors and outcomes of de novo cancers (excluding nonmelanoma skin cancer) after liver transplantation for primary sclerosing cholangitis. Transplantation 2017;101(8):1859\u20131866","journal-title":"Transplantation"},{"issue":"7","key":"10214_CR23","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1038\/ajg.2009.760","volume":"105","author":"N Pedersen","year":"2010","unstructured":"Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 2010;105(7):1480\u20131487","journal-title":"Am J Gastroenterol"},{"key":"10214_CR24","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cgh.2020.08.015","volume":"19","author":"B Lo","year":"2020","unstructured":"Lo B, Zhao M, Vind I, Burisch J. The risk of extraintestinal cancer in inflammatory bowel disease: a systematic review and meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2020;19:1117\u20131138","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10214_CR25","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","volume":"9","author":"V Annese","year":"2015","unstructured":"Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, et al. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis 2015;9(11):945\u2013965","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10214_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5009\/gnl16510","volume":"12","author":"C Palmela","year":"2018","unstructured":"Palmela C, Peerani F, Castaneda D, Torres J, Itzkowitz SH. Inflammatory bowel disease and primary sclerosing cholangitis: a review of the phenotype and associated specific features. Gut Liver 2018;12(1):17\u201329","journal-title":"Gut Liver"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10214-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-021-10214-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10214-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T15:51:53Z","timestamp":1634140313000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-021-10214-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,6]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10214"],"URL":"https:\/\/doi.org\/10.1007\/s12072-021-10214-6","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,6]]},"assertion":[{"value":"2 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by a research grant from Gilead Sciences Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Regional Ethical Board, Stockholm, Sweden (Dnr: 2016\/2343-31\/4, and 2017\/2041-32).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}